相关实验视频
Updated: Mar 3, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
从现实世界的远程医疗肥胖治疗诊所使用肥胖药物的24个月结果
Kathleen R Ruddiman1, Young-Rock Hong2, Jamy Ard1
1Department of Surgery, Bariatric and Weight Management Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Obesity (Silver Spring, Md.)
|March 2, 2026
概括
现实数据显示,抗肥胖药物 (AOM) 在18个月和24个月实现了显著的长期减肥. 远程医疗体重管理诊所有效地支持持续使用AOM和持续减肥.
科学领域:
- 肥胖药物 肥胖药物 肥胖药物
- 远程医疗服务是远程医疗服务.
- 临床结果研究研究的临床结果.
背景情况:
- 关于抗肥胖药物 (AOMs) 的长期疗效的现实世界数据有限.
- 远程医疗平台为体重管理提供了可扩展的解决方案.
- 在不同患者群体中评估持续的AOM有效性至关重要.
研究的目的:
- 评估AOMs的现实世界和长期疗效.
- 描述AOM使用18个月和24个月的临床结果.
- 评估远程医疗在支持长期体重管理中的作用.
主要方法:
- 使用AOMs对成年参与者的回顾性观察研究.
- 从远程医疗体重管理诊所收集的数据 (2022年1月 - 2024年12月).
- 对≥18个月 (n=11,675) 和≥24个月 (n=4317) 的参与者分析了体重变化.
主要成果:
- 18个月的平均总体体重减少为-18.53%,24个月的平均总体体重减少为-20.27%.
- 长期作用的AOM显示出比口服AOM更大的减肥趋势.
- 体重减轻持续,持续在18至24个月之间.
结论:
- 在18个月和24个月的真实世界AOM疗效与临床试验结果相比较.
- 远程医疗体重管理支持持续使用AOM和长期减肥.
- 这些发现支持了通过远程医疗提供的AOM的长期有效性.
相关概念视频
Drug Dosing: Obese Patients
316
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
316
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250

